----item----
version: 1
id: {2FD4D673-6C6C-4F09-903B-C0BA978DAF7A}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/21/BioMarin completes rolling NDA for Duchenne drug drisapersen
parent: {7C444FDC-DC63-4D50-B812-A158B8DC325D}
name: BioMarin completes rolling NDA for Duchenne drug drisapersen
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: f637119b-eeac-4eed-ac47-768af36fb025

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 61

BioMarin completes rolling NDA for Duchenne drug drisapersen 
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 60

BioMarin completes rolling NDA for Duchenne drug drisapersen
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1282

<p>BioMarin Pharmaceutical has completed its rolling new drug application (NDA) seeking approval from the FDA for drisapersen as a treatment for patients with the rare disease disorder Duchenne muscular dystrophy (DMD).</p><p>The disease is the most common fatal genetic disorder diagnosed in childhood &ndash; affecting about 1 in every 3,500 live male births, with about 20,000 new cases diagnosed globally each year. </p><p>Shares of BioMarin gained 3.9% earlier in the day on 27 April, before closing at $116.97, down $3.31, or 2.75%. </p><p>Given the unmet need in DMD, RW Baird analyst Christopher Raymond said he would not be surprised to see a decision from the FDA before the end of the year.</p><p>BioMarin actually obtained drisapersen through its acquisition of Prosensa, which <a href="http://www.scripintelligence.com/policyregulation/Drisapersen-rolling-NDA-gets-underway-Prosensa-rises-354415" target="_new">initiated</a> the rolling NDA this past October.</p><p>In <a href="http://www.scripintelligence.com/home/FDA-breakthrough-for-GSKProsensa-DMD-drug-drisapersen-rattles-Sarepta-344477" target="_new">June 2013</a>, drisapersen was declared a breakthrough therapy by the FDA &ndash; a process intended to expedite the regulatory process.</p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 223

<p>BioMarin Pharmaceutical has completed its rolling new drug application (NDA) seeking approval from the FDA for drisapersen as a treatment for patients with the rare disease disorder Duchenne muscular dystrophy (DMD).</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 60

BioMarin completes rolling NDA for Duchenne drug drisapersen
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150421T193330
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150421T193330
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150421T193330
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028555
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 61

BioMarin completes rolling NDA for Duchenne drug drisapersen 
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357993
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042335Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

f637119b-eeac-4eed-ac47-768af36fb025
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042335Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
